

Information in the press release below is intended for investors.

Isofol has obtained a request to call an extraordinary general meeting

GOTHENBURG, Sweden, November 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained a request to call an extraordinary general meeting for the election of additional board members.

Isofol has obtained a request to call an extraordinary general meeting from shareholders representing a minority of at least 10 percent in order to take a decision on the election of additional board members. The notice to the extraordinary general meeting will be announced as soon as is practically possible.

For further information, please contact

Isofol Medical AB (publ)

Mats Franzén, Chairman of the Board

E-mail: mats@efficere.se

Phone: +46 (0)704 47 29 09

Roger Tell, acting Chief Executive Officer

E-mail: roger.tell@isofolmedical.com

Phone: +46 (0) 760 29 39 11

The information was submitted for publication, through the agency of the contact person set out above, on November 9, 2023, at 12:55 CET.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com